logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Z

Zhi Peng

Peking University Cancer Hospital and Institute
H指数:34
被引数:4,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Diagnostic discordance and treatment-associated change of PD-L1 and CLDN18.2 in gastric cancer: a real-world analysis of paired biopsy–resection samples

更正：PD-L1和CLDN18.2在胃癌中的诊断不一致性及治疗相关性变化：配对活检-切除样本的真实世界分析

Gastric Cancer
IF5.1
2026-07-290
PREAI
Donghe Yu; Tong Xie; Siyuan Cheng; Cheng Liu; Yifan Zhang; Bohan Zhang; Yingxuan Wang; Yang Feng; Yuxin Wang; Hongchao Gao; Erke Gao; Yan Wang; Chengxi Shi; Lin Shen; Zhi Peng
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

savolitinib 在 MET 放大胃或胃食管连接处腺癌中的疗效：一项 II 期临床试验

Nature Medicine
IF50
2026-06-010
PRE
Zhi Peng; Tianshu Liu; Hua Wang; Jufeng Wang; Hongli Liu; Feng Ye; Enxiao Li; Jun Zhang; Baorui Liu; Rongbo Lin; Aiping Zhou; Zhenyang Liu; Huiting Xu; Qiong Wang; Zuoxing Niu; Ying Yuan; Yanru Qin; Xiujuan Qu; Yuxian Bai; Ning Liu; Hailong Liu; Chunmei Bai; Yueyin Pan; Shubin Wang; Tao Wu; Qinghua Pan; Diansheng Zhong; Hongxia Lu; Junye Wang; Zhiyu Wang; Ting Deng; Hongfeng Gou; Xiwen Huang; Sisi Fu; Puhan Lu; Jie Yu; Mengyang Hong; Qian Xu; Linfang Wang; Yongxin Ren; Songhua Fan; Lin Shen
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial

曲妥珠单抗德鲁替康在既往接受过治疗的中国人表皮生长因子受体2阳性局部晚期/转移性胃或胃食管结合部腺癌患者中的疗效（DESTINY-Gastric06）：一项单臂、多中心、II期试验的结果

eClinicalMedicine
IF10
2025-08-110
PREAI
Zhi Peng; Ping Chen; Jin Lu; Yiye Wan; Yulong Zheng; Feng Ye; Jianwei Yang; Ying Liu; Hongming Pan; Meili Sun; Qingxia Fan; Ying Yuan; Kai Chen; Zhuoer Sun; Han Tian; Ye Xia; Lin Shen
Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis

低PD-L1表达晚期胃癌患者一线治疗中，免疫检查点抑制剂联合化疗与单纯化疗的对比：一项系统评价和Meta分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-05-080
OA
Wang, Yuxin; Xie, Tong; Xiang, Shuai; Liu, Cheng; Cheng, Siyuan; Zhang, Bohan; Zhang, Yifan; Feng, Yang; Wang, Yingxuan; Yu, Donghe; Gao, Hongchao; Gao, Erke; Shen, Lin; Peng, Zhi
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

KN026（一种双特异性抗HER2抗体）与KN046（一种抗CTLA4/PD-L1抗体）联合治疗晚期HER2阳性非乳腺癌患者的有效性与安全性：一项Ib期和II期研究的合并分析

SIGNAL TRANSDUCTION AND TARGETED THERAPY
IF52.7
2025-03-190
OA
Liu, Dan; Gong, Jifang; Li, Jian; Qi, Changsong; Niu, Zuoxing; Liu, Bo; Peng, Zhi; Luo, Suxia; Wang, Xicheng; Wang, Yakun; Zhao, Rusen; Chen, Lilin; Deng, Ting; Li, Zhen; Chen, Lei; Fang, Meimei; Yang, Hongwei; Lu, Linzhi; Zhang, Yanming; Kang, Fengling; Xu, Ting; Zhang, Xiaotian
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

PD-1抗体camrelizumab联合apatinib和SOX作为AFP产生性胃或胃食管结合部腺癌患者的一线治疗（CAP 06）：一项多中心、单臂、II期临床试验

SIGNAL TRANSDUCTION AND TARGETED THERAPY
IF52.7
2025-03-140
OA
Wang, Yakun; Lu, Jialin; Chong, Xiaoyi; Wang, Chang; Chen, Xiaofeng; Peng, Zhi; Gu, Yanhong; Wang, Yizhuo; Wang, Xicheng; Li, Jian; Gong, Jifang; Qi, Changsong; Yuan, Jiajia; Lu, Zhihao; Lu, Ming; Zhou, Jun; Cao, Yanshuo; Chen, Yang; Zhang, Cheng; Hou, Zhiguo; Kou, Hongyi; Shen, Lin

研究方向

暂未获取到该数据
L
Lin Shen
H 指数:62论文数:827被引数:2.6万
J
Jifang Gong
H 指数:36论文数:226被引数:5,468
李健 封面图
李健
H 指数:34论文数:276被引数:4,777
张笑天 封面图
张笑天
H 指数:38论文数:186被引数:4,450
C
Changsong Qi
H 指数:28论文数:124被引数:3,357
L
Lin Shen
H 指数:57论文数:546被引数:1.8万
X
Xicheng Wang
H 指数:36论文数:331被引数:6,489
M
Ming Lu
H 指数:35论文数:206被引数:5,156
J
Jun Zhou
H 指数:23论文数:98被引数:2,493
Z
Zhihao Lü
H 指数:33论文数:211被引数:5,154